The Institute of Cancer Research, London, UK
Molecular Addictions in Cancer
We are interested in pre-clinical testing of targeted agents with chemistries that enhance BBB penetration. The goal is to establish the level of target engagement for these compounds that is necessary to induce a biological response, and use this information to determine whether this is achievable in patients. We are also, in collaboration with colleagues at the ICR, interested in developing quantitative PD biomarkers of target engagement using non-invasive approaches such as PET.
Existing collaborations relevant to drug delivery
Publications relevant to drug delivery
Stein S, Zhao R, Haeno H, Vivanco I, Michor F (2018) Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients. PLoS Comput Biol. Jan 2;14(1):e1005924. doi: 10.1371/journal.pcbi.1005924.
Vivanco I, Robins HI, Rohle D, et al. (2012) Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. May;2(5):458-71. doi: 10.1158/2159-8290.CD-11-0284
Email for contact details